BioCentury | Oct 2, 2020
Distillery Therapeutics

IL-12B monomers to treat multiple sclerosis, rheumatoid arthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS); rheumatoid arthritis (RA) Monomers of IL-12B, which can dimerize with itself, IL-12A or IL23P19, could treat autoimmune disorders including MS and RA. Relapsing-remitting MS patients had higher...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

...CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1 encephalitis, systemic knockout of CXCR2...
...II testing to treat solid tumors.TARGET/MARKER/PATHWAY: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 2 (CXCR2; IL8RB)EXPERIMENTAL...
...Boston, Claire Quang Massachusetts General Hospital Harvard Medical School Chemokine CXC motif ligand 1 (CXCL1) (GRO) (MGSA) CXC chemokine receptor 2 (CXCR2) (IL8RB) Infectious Encephalitis Herpes...
BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

Mylan, Biocon launch long-acting insulin biosimilar in U.S. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin glargine in the U.S. at a wholesale acquisition cost (WAC) of $147.98 per package of five...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis Inhibiting the chemokine receptor CXCR3 or its ligand CXCL9 could treat osteoporosis. In a medaka fish model of RANKL-induced osteoporosis, two CXCR3 inhibitor tool compounds reduced mineralization defects including resorption...
BioCentury | Jul 31, 2020

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing. The corporate venture fund...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...
Items per page:
1 - 10 of 430